Why is Bristol-Myers Squibb stock gaining today?
Bristol-Myers Squibb (BMY) stock rose 1.5% in pre-market trading after reporting Q3 2026 adjusted EPS of $1.35, beating estimates of $1.09–$1.10, and revenue of $13.07 billion, exceeding forecasts of $12.72 billion. The company raised its full-year 2026 revenue guidance to $49.75–$50.25 billion. Growth Portfolio revenue increased 12% year-over-year to $7.7 billion. The stock traded lower than its 52-week high ahead of earnings.
How this was made
The 30-second read
Why it matters
Traders can treat this as a same-day earnings/guidance repricing event: revenue guidance up and Growth Portfolio expansion support the bull case, while the EPS guidance trim is positioned as accounting/transaction-related rather than operational weakness.
Market read
A same-day earnings and guidance catalyst with specific numbers, plus an FDA approval milestone, is likely to drive immediate positioning and revisions to near-term expectations.
What to watch
The article highlights an acquired IPRD charge and a pipeline milestone (Zenbexus) but does not quantify how much future sales the approval will contribute, leaving valuation sensitive to subsequent uptake and late-stage readouts.
Background
The piece frames BMY’s pre-open gain as a response to its Q3 earnings beat, raised revenue guidance, and an FDA approval milestone for Zenbexus, while noting a headline EPS guidance cut tied to an acquired IPRD charge.
Ticker impact
Bristol-Myers Squibb reported Q3 2026 adjusted EPS of $1.35 vs ~$1.09-$1.10 consensus and raised full-year revenue guidance to $49.75B-$50.25B.
Likely upward pressure as the market re-rates operating momentum and treats the EPS guidance cut as largely non-operational (IPRD charge).
The article cites a clear EPS and revenue beat, explicit guidance raise for revenue, and attributes the EPS guidance reduction to a $0.60 acquired IPRD charge rather than deterioration in core performance.
Market effects
Reinforces positive read-through for large-cap pharma earnings quality and pipeline execution, potentially supporting sentiment toward oncology franchises.
Limited direct regional spillover; mainly affects US large-cap pharma sentiment during a risk-off pre-market.
Modest global relevance given the US-focused earnings/guidance catalyst and FDA approval reference.
Counterpoint
The full-year adjusted EPS guidance was trimmed, so the stock’s strength could fade if investors later focus on earnings-per-share rather than revenue momentum.
Key entities
- companyBristol-Myers Squibb
Reported Q3 2026 adjusted EPS and revenue beats, raised full-year 2026 revenue guidance, and referenced FDA approval of Zenbexus.
- productZenbexus
FDA-approved CELMoD agent for multiple myeloma, described as first-in-class in the article.
- business_segmentGrowth Portfolio
Portfolio cited as expanding 12% year-over-year to $7.7B in the quarter, driven by multiple branded therapies.
